紫杉醇脂质体在乳腺癌新辅助化疗中的应用研究  

Research on the application of paclitaxel liposome in the neoadjuvant chemotherapy of breast cancer

作　　者：徐雨佳[1] 方力[1] 

机构地区：[1]湖南省郴州市第一人民医院,湖南郴州423000

出　　处：《实用临床医药杂志》2011年第11期97-98,共2页Journal of Clinical Medicine in Practice

摘　　要：目的比较紫杉醇脂质体与传统紫杉醇在乳腺癌新辅助化疗中的疗效及不良反应。方法 62例接受新辅助化疗的乳腺癌患者随机分为2组:即实验组(n=31),紫杉醇脂质体治疗;对照组(n=31),紫杉醇治疗。比较2组患者临床疗效及不良反应发生率。结果 2组疗效差异无显著性。在血液学毒性方面,2组发生率差异无显著性。在周围神经毒性及过敏反应方面,试验组发生率明显低于对照组,差异有显著性。结论紫杉醇脂质体在乳腺癌新辅助治疗的过程中疗效与普通紫杉醇相似,但发生过敏反应几率明显减低,毒副反应可以耐受。Objective To compare the therapeutic effect and adverse reaction of paclitaxel liposome and paclitaxel in the neoadjuvant chemotherapy of breast cancer.Methods Sixty-two cases of breast cancer who accepted neoadjuvant chemotherapy were divided into two groups randomly,namely experimental group and control group.Patients in experimental group were treated by paclitaxel liposome.While patients in control group were treated with paclitaxel.Clinical efficacy and adverse reaction rates in this two groups were compared.Results Among the 62 cases,61 ones were suitable for the evaluation of the therapeutic effect and adverse reaction.Difference between two groups was not significant.The two groups had no significant difference in the incidence of hematologic toxicity.In the peripheral nerve toxicity and allergic reactions,the experimental group was significantly lower than the control group,the difference was significant.Conclusion The therapeutic effect of paclitaxel liposome in the neoadjuvant chemotherapy of breast cancer is similar to that of paclitaxel.But the incidence rate of allergy and toxic effect of paclitaxel liposome is much lower than that of paclitaxel.

关 键 词：紫杉醇脂质体 乳腺癌 新辅助化疗 

分 类 号：R737.9[医药卫生—肿瘤]